Prognosis
Prognosis is the anticipated course and outcome of a disease or clinical condition.
Prognosis is the anticipated course and outcome of a disease or clinical condition. It may describe the likelihood of recovery, disease progression, recurrence, treatment response, functional independence, complications, or death over a defined period. In clinical practice, prognosis is not a single fixed prediction; it is an estimate that changes as new information becomes available, including the patient’s age, comorbidities, disease severity, pathological features, treatment, and response to treatment.
As a clinical metric, prognosis is often expressed through outcomes such as overall survival, disease-specific survival, mortality, progression-free survival, recurrence, or functional recovery. Prognostic assessment may use clinical variables, imaging, histopathology, circulating biomarkers, molecular signatures, or statistical and artificial-intelligence models. In oncology, factors such as tumor stage, metastasis, proliferation, invasion, the tumor microenvironment, receptor status, and treatment exposure may influence prognosis. In other diseases, biomarkers of metabolism, inflammation, or organ dysfunction may be evaluated for their association with short- or long-term outcomes. A prognostic marker estimates future outcome, whereas a predictive marker is primarily intended to indicate whether a patient is likely to benefit from a particular treatment such as chemotherapy, immunotherapy, or a checkpoint inhibitor.
Rebuilt from PubMed 18 Sept 2026 · no new papers today
Where the papers sit
11 papers study prognosis directly. The themes below are drawn from those 11. 1 new direction follows.
-
Prognostic Biomarkers Across Diseases : Metabolic signatures, circulating biomarkers, plasma proteomics and explainable prediction models are being tested for prognosis across cancer, cardiovascular, respiratory, skeletal and neurosurgical settings. Validation remains the recurring goal rather than a single biological mechanism. 6 papers · 54.5%
-
Adjuvant Therapy in Breast Cancer : Real-world adjuvant treatment is being compared across receptor-defined breast cancer, with regional chemotherapy variation in HR+/HER2- disease and pertuzumab eligibility in HER2+ disease linked to prognosis. Treatment uptake and subtype-specific outcomes recur. 2 papers · 18.2%
-
Others — Clinical Prognosis and Immunology : Melanoma cohorts and surgery for solitary metastatic bone disease address staging, comorbidity and outcomes, while uveitis work concerns corneal and tear-film immunology. The cluster shares clinical outcome assessment but no common disease or biological direction. 3 papers · 27.3%
Prognostic prediction becomes a tool for selecting treatment intensity rather than only estimating outcome
The pituitary adenoma radiosurgery study uses THINKERS-PA to predict tumor progression, biochemical remission, endocrine morbidity, and other outcomes while simulating prescription doses 42693349Sep. Prognosis is ordinarily used here to describe risk or compare outcomes after treatment; this study instead makes individualized prognostic estimates part of treatment planning by evaluating how different doses might affect those predicted outcomes. The result is a shift toward using prognosis to guide radiosurgical prescription, not merely to classify patients after a treatment decision has been made.
Recent Findings on prognosis
A study of bronchiolitis investigated whether adrenomedullin, measured as mid-regional pro-adrenomedullin (MR-proADM), could serve as a predictor of disease severity and prognosis. The work places prognosis within biomarker-based risk stratification for respiratory disease, rather than limiting prognostic assessment to clinical examination alone 42742823Sep.
In stroke, researchers integrated multi-omics Mendelian randomization, neuroimaging mediation, and functional validation to identify PYGL as a neuroprotective causal gene relevant to stroke prognosis. The study connects genetic evidence and neuroimaging-related pathways with outcome prediction, extending prognostic research beyond conventional clinical variables 42744168Sep.
A multicenter retrospective cohort study examined the 28-day prognostic value of iron-metabolism biomarkers in patients with severe acute coronary syndrome. Using the MIMIC and eICU clinical databases, the investigators assessed serum iron, ferritin, transferrin, and total iron-binding capacity as candidate indicators of short-term outcome. This work illustrates the use of routinely collected biochemical data to study mortality and other near-term clinical outcomes in cardiovascular disease 42736313Sep.
In osteoporosis, an explainable plasma-proteomics machine-learning study addressed diagnosis, prognosis, and protein biomarker discovery using data from the UK Biobank. The combination of proteomic measurements and interpretable artificial intelligence reflects a broader effort to produce prognostic models whose biomarker contributions can be examined rather than treated as opaque predictions 42667149Aug.
A colon adenocarcinoma study analyzed gene signatures related to mitochondrial metabolism and succinylation. Its objectives were to identify biomarkers associated with prognosis and drug resistance and to establish a prognostic model. The study therefore links tumor-cell metabolism and post-translational regulation with outcome prediction and treatment-response assessment in colorectal cancer 42176930May.
A retrospective cohort study of 355 patients with melanoma in Xinjiang, China, characterized clinicopathological features and prognosis. This work represents disease-specific clinical outcome assessment, in which demographic and pathological characteristics are examined in relation to the subsequent course of cancer, including progression or survival-related outcomes 42715204Sep.
THINKERS-PA was developed as a mixture-of-experts framework for outcome prediction and prescription-dose simulation after gamma-knife radiosurgery for pituitary adenoma. The reported work focused on internal validation of the framework, placing prognosis alongside treatment planning and model validation rather than considering it solely as a descriptive clinical endpoint 42693349Sep.
A retrospective study of hemiarthroplasty for a solitary metastasis of the proximal humerus examined whether age influenced prognosis and functional recovery after shoulder arthroplasty. The study therefore considers prognosis in the context of metastatic disease, orthopedic intervention, and post-treatment function, where survival-related outcomes and recovery of physical performance may both be clinically important 42619530Aug.
A protocol for a systematic review and meta-analysis of anterior uveitis described the intended synthesis of immunological features in the cornea and tear film. The review will assess the potential utility of these features as biomarkers for disease classification, prognosis, and monitoring of treatment responsiveness. This places prognosis within biomarker development for inflammatory eye disease and links it with treatment monitoring rather than only with mortality or survival 42586731Aug.
In early HR-positive/HER2-negative breast cancer, investigators examined regional variation in chemotherapy use across Sweden and its association with prognosis. The study addresses how treatment patterns and healthcare-region differences may relate to outcomes, with prognosis considered alongside chemotherapy exposure and the clinical characteristics used to guide treatment 42587318Aug.
A nationwide population-based study evaluated the incidence and prognosis of HER2-positive breast cancer in patients eligible for adjuvant pertuzumab during the modern era of neoadjuvant therapy. The analysis considered patients treated after primary resection and those receiving preoperative treatment, linking receptor-defined disease, treatment sequence, and eligibility for targeted therapy with subsequent clinical outcomes 42288056Jun.
Taken together, these publications primarily extend the theme of prognostic biomarker validation, applying metabolic signatures, circulating proteins, genetic features, and clinical variables across cancer, cardiovascular, neurological, respiratory, and skeletal disease. They also extend the theme of breast cancer treatment patterns through analyses of chemotherapy use, receptor status, neoadjuvant therapy, and adjuvant pertuzumab eligibility. The melanoma, pituitary adenoma, orthopedic metastasis, and anterior uveitis studies broaden prognosis as a general framework for clinical outcome assessment involving metastasis, age, functional recovery, immunological biomarkers, treatment response, and model validation.
Written from 11 PubMed abstracts, each one cited by PMID above. Published: 2026-09-17. Drafted by language models from published abstracts; not medical advice.